Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.

SAMURAI : revenue, balance sheet and financial ratios

SAMURAI is a French company founded 3 years ago, specialized in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques. Based in GRAND-FOUGERAY (35390), this company of category PME shows in 2025 a net income positive of 178 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.

Data updated on 2026-05-02

Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy

Financial history - SAMURAI (SIREN 919203398)
Indicator 2025
Revenue N/C
Net income 177 888 €
EBITDA N/C
Net margin N/C

Revenue and income statement

In 2025, SAMURAI generates positive net income of 178 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.

Net income (2025) ?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax

177 888 €

Loading income statement...

Chart evolution

Show :

Assets

Loading data...

Liabilities

Loading data...

Solvency and debt ratios

The debt ratio (= Financial debt / Equity x 100) stands at 98%. Debt level is high: negotiating margin with banks is reduced. Financial autonomy (= Equity / Total assets x 100) reaches 43%. This high autonomy means the company finances most of its assets through equity, a sign of strength.

Debt ratio (2025) ?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low
50-100% : Moderate
> 100% : High

98.07%

Financial autonomy (2025) ?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy
20-30% : Average
< 20% : Low

43.37%

Asset age ratio (2025) ?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Interpretation
< 50% : Recent assets
50-70% : Normal wear
> 70% : Aging assets

88.1%

Solvency indicators evolution
SAMURAI

Sector positioning

Debt ratio
98.07 2025
2025
Q1: 0.0
Med: 3.67
Q3: 28.55
Watch

In 2025, the debt ratio of SAMURAI (98.07) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.

Financial autonomy
43.37% 2025
2025
Q1: 26.28%
Med: 43.48%
Q3: 62.04%
Average

In 2025, the financial autonomy of SAMURAI (43.4%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.

Liquidity ratios

The liquidity ratio (= Current assets / Current liabilities) stands at 663.38. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.

Liquidity ratio (2025) ?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good
1-1.5 : Fair
< 1 : Liquidity risk

663.375

Liquidity indicators evolution
SAMURAI

Sector positioning

Liquidity ratio
663.38 2025
2025
Q1: 147.44
Med: 215.05
Q3: 310.05
Excellent

In 2025, the liquidity ratio of SAMURAI (663.38) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.

Positioning of SAMURAI in its sector

Comparison with sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Valuation estimate

Based on 124 transactions of similar company sales (all years), the value of SAMURAI is estimated at 146 137 € (range 55 621€ - 533 676€). This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.

Estimated enterprise value 2025
124 transactions
55k€ 146k€ 533k€
146 137 € Range: 55 621€ - 533 676€
NAF 5 all-time

Valuation method used

Net Income Multiple
177 888 € × 0.8x = 146 138 €
Range: 55 621€ - 533 677€

Only this financial indicator is available for this company.

How is this estimate calculated?

This estimate is based on the analysis of 124 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.

  • EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
  • Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
  • Net Income Multiple: Relevant for mature companies with stable results.

This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).

Similar companies (Commerce de gros (commerce interentreprises) de produits pharmaceutiques)

Compare SAMURAI with other companies in the same sector:

Voir toutes les statistiques du secteur Commerce de gros (commerce interentreprises) de produits pharmaceutiques

Frequently asked questions about SAMURAI

What is the revenue of SAMURAI ?

The revenue of SAMURAI is not publicly disclosed (confidential accounts filed with INPI).

Is SAMURAI profitable?

Yes, SAMURAI generated a net profit of 178 k€ in 2025.

Where is the headquarters of SAMURAI ?

The headquarters of SAMURAI is located in GRAND-FOUGERAY (35390), in the department Ille-et-Vilaine.

Where to find the tax return of SAMURAI ?

The tax return of SAMURAI is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).

In which sector does SAMURAI operate?

SAMURAI operates in the sector Commerce de gros (commerce interentreprises) de produits pharmaceutiques (NAF code 46.46Z). See the 'Sector positioning' section above to compare the company with its competitors.